AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune SA (NASDAQ: ACIU) said it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of its Phase 2 VacSYn trial of ACI-7104 in early Parkinson’s disease by 2 years to assess long-term safety and efficacy. Final Part 1 results (to week 104) are expected in H2 2026.
Non-dilutive funding supports longer-duration safety/efficacy data collection for ACI-7104, potentially strengthening the clinical narrative ahead of final Part 1 readout.
AC Immune announced a $4M grant to extend Part 1 of its Phase 2 VacSYn trial of ACI-7104 for 2 additional years in early Parkinson’s.
Near-term sentiment likely positive; material upside depends on how the extended dataset de-risks disease-modifying claims by H2 2026.
Background
VacSYn Part 1 is a Phase 2 study in early Parkinson’s using ACI-7104 (anti-alpha-syn active immunotherapy); positive interim results were reported in Dec 2025.
Why it matters
The grant funds extending Part 1 for an additional 2 years to generate long-term safety/efficacy data, with final Part 1 results expected in H2 2026 (week-104).
Market relevance
Non-dilutive funding plus a longer follow-up window can improve the quality of the clinical evidence base into the next major readout (H2 2026).
Market effects
Reinforces investor focus on anti-alpha-synuclein immunotherapies and the value of long-term safety datasets in early PD.
Primarily impacts US-listed biotech sentiment; grant is from a private foundation with no stated geographic market effects.
Highlights continued global funding and momentum for neurodegenerative precision-prevention programs.
Alternative perspectives
A $4M grant may be helpful but is unlikely to change valuation materially versus the larger question of whether extended follow-up confirms disease-modifying benefit.
Traders may discount the news if the trial extension does not alter endpoints or if interim signals later prove less durable than hoped; also watch for any future dilution/financing needs despite non-dilutive funding.
Key entities
- companyAC Immune SA
Clinical-stage biopharmaceutical company developing ACI-7104 for early Parkinson’s via VacSYn Phase 2.
- drug_programACI-7104
Anti-alpha-synuclein active immunotherapy; Part 1 extension targets long-term safety/efficacy in early PD.
- funderVijay and Marie Goradia Charitable Foundation
Provides a $4M research grant to support the VacSYn Part 1 extension.
